CYP7A1 Rekombinanter Antikörper

CYP7A1 Rekombinant Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

CloneNo.

250554G10

Kat-Nr. : 86045-2-RR

Synonyme

Cholesterol 7-alpha-hydroxylase, Cholesterol 7-alpha-monooxygenase, CP7A, CYP7, CYPVII

---

• 

  WB analysis using 86045-2-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 86045-2-RR (CYP7A1 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

• 

  Affinity and Kinetic Characterization of 86045-2-RR

  Biolayer interferometry (BLl) kinetic assays of 86045-2-RR against Human CYP7A1 were performed. The affinity constant is below 1 pM.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: K-562-Zellen, HepG2-Zellen, HuH-7-Zellen, L02-Zellen, Mauslebergewebe, SMMC-7721-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:2000-1:10000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

86045-2-RR bindet in WB, ELISA CYP7A1 und zeigt Reaktivität mit human, Maus

• Getestete Reaktivität: human, Maus
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Rekombinant
• Typ: Antikörper
• Immunogen: CYP7A1 fusion protein Ag12572
• Vollständiger Name: cytochrome P450, family 7, subfamily A, polypeptide 1
• Berechnetes Molekulargewicht: 504 aa, 58 kDa
• Beobachtetes Molekulargewicht: 58 kDa
• GenBank-Zugangsnummer: BC101777
• Gene symbol: CYP7A1
• Gene ID (NCBI): 1581
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

CYP7A1 (Cytochrome P450 Family 7 Subfamily A Member 1), is a cholesterol 7alpha-hydroxylase, catalyzing the first and rate-limiting step in the neutral or classic pathway for bile acid biosynthesis. CYP7A1 is a postulated gene modifier of colorectal cancer risk and target for the therapeutic bile acid, ursodeoxycholic acid (UDCA). The CYP7A1 enzyme controls the rate-limiting step of the catabolism of cholesterol into bile acids in the liver.